Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Estrogen and progesterone receptor expression in the mammary gland tumors.

Moise M, Buruian MM, Ilie C, Zamfir CL, Folescu R, Motoc AG.

Rom J Morphol Embryol. 2013;54(4):961-8.

2.
3.

Multicentric mammary carcinoma: evidence of monoclonal proliferation.

Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA.

Cancer. 2002 Apr 1;94(7):1910-6.

4.

Immunohistochemical determination of estrogen and progesterone receptors in canine mammary tumors.

Toniti W, Buranasinsup S, Kongcharoen A, Charoonrut P, Puchadapirom P, Kasorndorkbua C.

Asian Pac J Cancer Prev. 2009;10(5):907-11.

5.

Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.

Shahi KS, Bhandari G, Singh A.

J Cancer Res Ther. 2011 Jan-Mar;7(1):19-22. doi: 10.4103/0973-1482.80433.

6.
8.

Correlation of sonographic features of invasive ductal mammary carcinoma with age, tumor grade, and hormone-receptor status.

Aho M, Irshad A, Ackerman SJ, Lewis M, Leddy R, Pope TL, Campbell AS, Cluver A, Wolf BJ, Cunningham JE.

J Clin Ultrasound. 2013 Jan;41(1):10-7. doi: 10.1002/jcu.21990. Epub 2012 Sep 20.

10.

Immunohistochemical evaluation of hormone receptors with predictive value in mammary carcinomas.

Pleşan DM, Georgescu M, Georgescu CV, Pătrană N, Nină T, Pleşan C.

Rom J Morphol Embryol. 2011;52(4):1331-6.

11.

Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F.

J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338.

12.

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.

PMID:
7496840
13.

[Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].

Mchedlishvili MIu, Gabunia UA, Makharoblidze ER, Burnadze KT, Piradashvili DZ.

Georgian Med News. 2005 Feb;(119):65-7. Russian.

PMID:
15834186
14.
15.

Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.

Gokce H, Durak MG, Akin MM, Canda T, Balci P, Ellidokuz H, Demirkan B, Gorken IB, Sevinc AI, Kocdor MA, Saydam S, Harmancioglu O.

Breast J. 2013 Jul-Aug;19(4):374-81. doi: 10.1111/tbj.12128. Epub 2013 May 29.

PMID:
23714006
16.

Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity?

Kiani J, Khan A, Khawar H, Shuaib F, Pervez S.

Pathol Oncol Res. 2006;12(4):223-7. Epub 2006 Dec 25.

17.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
18.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
20.

Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.

Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, Boualga K, Benbrahim W, Mahfouf H.

Breast Dis. 2015;35(2):95-102. doi: 10.3233/BD-150398.

PMID:
25736840

Supplemental Content

Support Center